Probable levetiracetam-related serum alkaline phosphatase elevation
© Xiong et al.; licensee BioMed Central Ltd. 2012
Received: 11 December 2011
Accepted: 17 September 2012
Published: 20 September 2012
Levetiracetam (LEV) is an antiepileptic drug with a favorable tolerability and safety profile with little or no effect on liver function.
Here, we reported an epileptic pediatric patient who developed a significant elevation in serum alkaline phosphatase level (ALP) during LEV monotherapy. Moreover, the serum ALP level was surprisingly decreased to normal after LEV discontinuation. The Naranjo Adverse Drug Reaction Probability Scale score was 6, indicating firstly LEV was a probable cause for the increased serum ALP.
Cautious usage and concerns of the LEV-associated potential ALP elevation should be considered when levetiracetam is prescribed to epilepsy patients, especially pediatric patients.
KeywordsLevetiracetam Serum alkaline phosphatase Hepatotoxicity Antiepileptic drugs Epilepsy
Levetiracetam (LEV), structurally similar to the nootropic drug piracetam, is an anticonvulsant medication used for epilepsy treatment. It has been approved by the US Food and Drug Administration as adjunctive therapy for partial seizures in adult and children over 4 years of age with favorable tolerability and safety [1, 2]. Moreover, previous studies have been indicated that its efficacy and safety are available in infant and pediatric patients younger than 4 years of age as well [3, 4]. It has recently been approved in the European Union as a monotherapy treatment for partial seizures, or as an adjunctive therapy for partial, myoclonic and tonic-clonic seizures .
The exactly underlying mechanisms by which LEV exerts its antiepileptic effect have not yet completely understood. Nevertheless, the drug binding to SV2A, a synaptic vesicle protein , inhibits nerve conduction across synapses . The common untoward reactions of LEV include asthenia, convulsion, dizziness and somnolence . However, the liver enzyme induction effect of LEV has never been literally reported before. Here, we presented the first case in which elevated serum ALP was highly associated with LEV administration.
A 10-month-old Han Chinese girl (weight 9 kg) with a history of head trauma was treated conservatively after being diagnosed as intracranial hemorrhage (brain computed tomography scan, brain CT). The patient had been suffered from convulsive attacks (more than 10 episodes/day in the recent 7 days) for 1 week when she was admitted to the Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The seizure was characterized as paroxysmal attacks of perioral cyanosis and limbs convulsion, lasting for 2 minutes with spontaneous remission. Her vital signs was stable and within normal limits, and phy-sical and neurological examination revealed no remarkable abnormalities.
Five months after LEV treatment, an elevation of serum ALP level (1613 U/L) was accidentally found from a periodical blood biochemistry test without any other abnormalities. One week later, the repeated laboratory test showed that serum ALP level was significantly increased to 4557U/L, accompanied by slightly elevated levels of creatine kinase (81 U/L, 26-140 U/L), creatine kinase-MB activity (50 U/L, 0-24 U/L), lactate dehydrogenase (320 U/L, 109-245 U/L) and bone ALP (>300 U/L, 0-200 U/L). However, no discomfort or seizure activity was observed in this patient. Other related auxiliary examinations included parathyrin level (20.9 pg, 15-68.3 pg), abdominal ultrasound and CT (liver, hepatobiliary system, gallbladder, spleen and kidney), lower extremity long bones X-ray and EEG (Figure 2B) were all normal. Also, no concomitant symptoms and other changes could explain the elevated serum ALP. Therefore, considering the possibility that LEV might be associated with the elevated serum ALP, LEV was discontinued. Surprisingly, the serum ALP level was decreased to 1156 U/L 10 days later. Twenty days after the discontinuation, the patient’s serum ALP level returned to normal (423 U/L). Six months follow-up indicated that the patient was fully recovered, manifesting no recurrent seizure attack or liver function abnormality. She was well developed and nourished during that period, observing from her height, weight, and body mass index.
Naranjo Adverse Drug Reaction Probability Scale  was employed to assess the probability correlation of LEV administration and elevated serum ALP. A score of 6 was obtained (Additional file 2), demonstrating LEV was a “probable” cause for the serum ALP elevation, and LEV even possibly led to liver function abnormality although LEV rechallenge was not executed in this patient.
Discussion and conclusions
Here, we reported a pediatric epilepsy patient who developed elevated serum ALP after LEV treatment. To our knowledge, this is the first report about probable LEV-associated ALP elevation. Before LEV was administrated, the patient’s serum ALP level was normal (162 U/L). The patient was asymptomatic during the intervening period, thus, no other medication was added. As LEV was the only medication for the patient, it was suspected to be the offending agent responsible for the increased ALP level. Moreover, the serum ALP level decreased gradually and returned to normal after the discontinuation of LEV therapy.
The serum ALP activity is commonly measured in clinical chemistry laboratories. Increased values are often associated with disorders of the skeletal or hepatobiliary system, or other possibilities such as leukemia and hyperthyroidism . In our case, all of these potentialities were ruled out by the clinical presentations and auxiliary examination results for parathyrin level, liver, hepatobiliary system, gallbladder, spleen, kidney and lower extremity long bones of this patient. Additionally, history of toxic substances exposure and other drug abuse was absent. Besides, the patient’s increased serum ALP lever was rapidly returned to normal range after discontinuation of LEV, indicating the association between elevated serum ALP and LEV treatment should not be coincidental. Furthermore, the Naranjo Adverse Drug Reaction Probability Scale assessment further confirmed that LEV was a “probable” cause for the serum ALP elevation.
Serious liver function impairment could be rarely observed in patients taking AEDs. Among the traditional AEDs, valproate, which requires routine blood monitoring, can cause hepatotoxicity. Felbamate is the only second-generation AEDs associated with hepatotoxicity that may be fatal. However, liver function impairment has never been reported with LEV. LEV shows rapid absorption, does not bind serum proteins and has linear pharmacokinetics. More than 60% of absorbed LEV can be excreted by the kidneys, approximately 25% is metabolized by metabolized through esterase’s in the blood, less than 3% is plasma protein-bound . Previous study even reported that LEV might affect bone metabolism of both neurologically impaired children and healthy children . Moreover, increased clearance of LEV is reportedly associated with younger age . Although LEV rarely distributes into liver and skeletal sites, nor has displayed any enzyme induction effects in human liver cell tissue , it is necessary to present this case and raise the concern of potential hepatotoxicity of LEV.
In summary, we introduced the first case which showed elevated serum ALP level was highly associated with LEV administration. However, it is difficult to confirm the relevance between LEV and serum ALP elevation. Further study is needed extremely to assess the potential hepatotoxicity of LEV in pediatric patients.
Written informed consent was obtained from the patient and her parents for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Series Editor of this journal.
Computed tomography scan.
This work was supported by grant (200960323134) from the Wuhan Science and Technology Bureau (to YH), grants 30870866, 81071021 and 31171211 from the National Natural Science Foundation of China (to TW), grant 81200983 from the National Natural Science Foundation of China (to NX) and grant 2012B09 from the China Medical Foundation (to NX).
- Leppik IE: Issues in the treatment of epilepsy. Epilepsia. 2001, 42 (Suppl 4): 1-6.View ArticlePubMedGoogle Scholar
- Wheless JW: Levetiracetam in the treatment of childhood epilepsy. Neuropsychiatr Dis Treat. 2007, 3 (4): 409-421.PubMedPubMed CentralGoogle Scholar
- Krief P, Li K, Maytal J: Efficacy of levetiracetam in children with epilepsy younger than 2 years of age. J Child Neurol. 2008, 23 (5): 582-584. 10.1177/0883073807309781.View ArticlePubMedGoogle Scholar
- Li S, Cao J, Xiao N, Cai F: Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. J Child Neurol. 2010, 25 (5): 609-613. 10.1177/0883073809342489.View ArticlePubMedGoogle Scholar
- Perucca E: Designing clinical trials to assess antiepileptic drugs as monotherapy: difficulties and solutions. CNS Drugs. 2008, 22 (11): 917-938. 10.2165/00023210-200822110-00003.View ArticlePubMedGoogle Scholar
- Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B: The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004, 101 (26): 9861-9866. 10.1073/pnas.0308208101.View ArticlePubMedPubMed CentralGoogle Scholar
- Rogawski MA: Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006, 69 (3): 273-294. 10.1016/j.eplepsyres.2006.02.004.View ArticlePubMedPubMed CentralGoogle Scholar
- Briggs DE, French JA: Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf. 2004, 3 (5): 415-424. 10.1517/14740322.214.171.1245.View ArticlePubMedGoogle Scholar
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30 (2): 239-245. 10.1038/clpt.1981.154.View ArticlePubMedGoogle Scholar
- Narayanan S: Serum alkaline phosphatase isoenzymes as markers of liver disease. Ann Clin Lab Sci. 1991, 21 (1): 12-18.PubMedGoogle Scholar
- Dahlin MG, Wide K, Ohman I: Age and comedications influence levetiracetam pharmacokinetics in children. Pediatr Neurol. 2010, 43 (4): 231-235. 10.1016/j.pediatrneurol.2010.05.008.View ArticlePubMedGoogle Scholar
- Borusiak P, Langer T, Heruth M, Karenfort M, Bettendorf U, Jenke AC: Antiepileptic Drugs and Bone Metabolism in Children: Data from 128 Patients. J Child Neurol. 2012, 10.1177/0883073812443005.Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/12/97/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.